Kwon Y W, Zhong Q, Wei X Y, Zheng W, Triggle D J
Department of Biochemical Pharmacology, School of Pharmacy, State University of New York, Buffalo 14260.
Naunyn Schmiedebergs Arch Pharmacol. 1990 Jan-Feb;341(1-2):128-36. doi: 10.1007/BF00195069.
The Ca2+ channel antagonistic potencies of tiamdipine [2-(2-aminoethylthio)methyl-3-carboethoxy-5-carbomethoxy-6-m ethyl-4-(3- nitrophenyl)-1,4-dihydropyridine] and nifedipine [2,6-dimethyl-3,5-dicarbomethoxy-4-(2-nitrophenyl)-1,4-dihydrop yri dine] analogs bearing phenyl ring substituents were studied using pharmacologic and radioligand binding techniques. Additionally, analogs of tiamdipine possessing (2-aminoethylthio)methyl-, (2-acetamidoethylthio)methyl- and (2-pyrrolidinylmethylthio)methyl- groups at the C2 position of the 1,4-dihydropyridine ring have been studied. Tiamdipine and nifedipine analogs inhibited K(+)-induced contractile responses in rat tail artery. IC50 values of 4-phenyl ring substituted 2-(2-aminoethylthio)methyl tiamdipine analogs ranged from 10(-7) mol/l to 10(-8) mol/l. However, the corresponding 4-phenyl ring substituted nifedipine analogs covered a wider range of potency from 10(-6) mol/l to 10(-9) mol/l. KI values of the corresponding tiamdipine analogs for the inhibition of specific [3H]PN 200-110 [(+)-[3H]isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5- methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate] binding ranged from 10(-7) mol/l to 10(-9) mol/l in guinea pig ileal and rat heart membranes and rat brain synaptosomes. The two stereoisomers of tiamdipine and its analog 2-(2-acetamidoethylthio)methyl-3-carboethoxy-5-carbomethoxy- 6-methyl-4-(3- nitrophenyl)-1,4-dihydropyridine, and the four stereoisomers of 2-(2-pyrrolidinylmethylthio)methyl-3-carboethoxy-5-carbom eth oxy-6-methyl-4-(3- nitrophenyl)-1,4-dihydropyridine showed high stereoselectivity ratios of approximately (-)/(+) = 100 and 1000 in pharmacologic and binding experiments, respectively. The inhibitory actions of 2-(2-aminoethylthio)methyltiamdipine analogs against K(+)-induced contractile responses in rat tail artery developed very slowly requiring at least 2 h for maximum effect.(ABSTRACT TRUNCATED AT 250 WORDS)
采用药理学和放射性配体结合技术,研究了含有苯环取代基的硫氮䓬地平[2-(2-氨基乙硫基)甲基-3-乙氧羰基-5-甲氧羰基-6-甲基-4-(3-硝基苯基)-1,4-二氢吡啶]和硝苯地平[2,6-二甲基-3,5-二甲氧羰基-4-(2-硝基苯基)-1,4-二氢吡啶]类似物的钙离子通道拮抗活性。此外,还研究了在1,4-二氢吡啶环C2位含有(2-氨基乙硫基)甲基、(2-乙酰氨基乙硫基)甲基和(2-吡咯烷基甲基硫基)甲基的硫氮䓬地平类似物。硫氮䓬地平和硝苯地平类似物抑制大鼠尾动脉中钾离子诱导的收缩反应。4-苯环取代的2-(2-氨基乙硫基)甲基硫氮䓬地平类似物的IC50值范围为10(-7)mol/L至10(-8)mol/L。然而,相应的4-苯环取代的硝苯地平类似物的活性范围更广,为10(-6)mol/L至10(-9)mol/L。在豚鼠回肠、大鼠心脏膜和大鼠脑突触体中,相应的硫氮䓬地平类似物对特异性[3H]PN 200-110[(+)-[3H]异丙基-4-(2,1,3-苯并恶二唑-4-基)-1,4-二氢-5-甲氧基羰基-2,6-二甲基-3-吡啶羧酸酯]结合的抑制作用的KI值范围为10(-7)mol/L至10(-9)mol/L。硫氮䓬地平及其类似物2-(2-乙酰氨基乙硫基)甲基-3-乙氧羰基-5-甲氧羰基-6-甲基-4-(3-硝基苯基)-1,4-二氢吡啶的两种立体异构体,以及2-(2-吡咯烷基甲基硫基)甲基-3-乙氧羰基-5-甲氧羰基-6-甲基-4-(3-硝基苯基)-1,4-二氢吡啶的四种立体异构体,在药理学和结合实验中分别显示出约(-)/(+)=100和1000的高立体选择性比率。2-(2-氨基乙硫基)甲基硫氮䓬地平类似物对大鼠尾动脉中钾离子诱导的收缩反应的抑制作用发展非常缓慢,至少需要2小时才能达到最大效果。(摘要截短至250字)